IL142582A0 - Enhanced vaccines - Google Patents
Enhanced vaccinesInfo
- Publication number
- IL142582A0 IL142582A0 IL14258299A IL14258299A IL142582A0 IL 142582 A0 IL142582 A0 IL 142582A0 IL 14258299 A IL14258299 A IL 14258299A IL 14258299 A IL14258299 A IL 14258299A IL 142582 A0 IL142582 A0 IL 142582A0
- Authority
- IL
- Israel
- Prior art keywords
- immunogenic polypeptides
- methods
- mammal
- ige
- nucleic acid
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 4
- 230000002163 immunogen Effects 0.000 abstract 5
- 229920001184 polypeptide Polymers 0.000 abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 241000124008 Mammalia Species 0.000 abstract 4
- 239000000463 material Substances 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10665298P | 1998-11-02 | 1998-11-02 | |
| US09/401,636 US6913749B2 (en) | 1998-11-02 | 1999-09-22 | Immunogenic polypeptides for inducing anti-self IgE responses |
| PCT/SE1999/001896 WO2000025722A2 (en) | 1998-11-02 | 1999-10-21 | ENHANCED VACCINES COMPRISING SELF AND NON-SELF IgE PORTIONS OR DIMERIC ANTIGENS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL142582A0 true IL142582A0 (en) | 2002-03-10 |
Family
ID=26803871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL14258299A IL142582A0 (en) | 1998-11-02 | 1999-10-21 | Enhanced vaccines |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US6913749B2 (da) |
| EP (1) | EP1135158B1 (da) |
| JP (2) | JP4205861B2 (da) |
| KR (1) | KR100559918B1 (da) |
| AT (1) | ATE314087T1 (da) |
| AU (1) | AU771889B2 (da) |
| CA (1) | CA2348756A1 (da) |
| DE (1) | DE69929240T2 (da) |
| DK (1) | DK1135158T3 (da) |
| ES (1) | ES2255325T3 (da) |
| HK (1) | HK1042844A1 (da) |
| HU (1) | HUP0105392A3 (da) |
| IL (1) | IL142582A0 (da) |
| NO (1) | NO20012135L (da) |
| NZ (1) | NZ511079A (da) |
| PL (1) | PL348611A1 (da) |
| PT (1) | PT1135158E (da) |
| WO (1) | WO2000025722A2 (da) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7658101A (en) * | 2000-07-28 | 2002-02-13 | Cytos Biotechnology Ag | Compositions for inducing self-specific anti-ige antibodies and uses thereof |
| EP2361635A3 (en) * | 2000-08-30 | 2011-09-14 | Pfizer Products Inc. | Anti IgE vaccines |
| US20040156838A1 (en) * | 2000-09-06 | 2004-08-12 | Steen Klysner | Method for down-regulating ige |
| PL206976B1 (pl) | 2001-02-20 | 2010-10-29 | Ortho Mcneil Pharm Inc | Sposoby wytwarzania zawiesiny CD8⁺ do stosowania w leczeniu podmiotu z rakiem lub czerniakiem, sposób produkcji nie występującej naturalnie komórki i nie występująca naturalnie linia komórkowa |
| US20040071671A1 (en) | 2001-02-20 | 2004-04-15 | Leturcq Didier J. | Cell therapy method for the treatment of tumors |
| JP2005516581A (ja) * | 2001-05-15 | 2005-06-09 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 自己免疫およびアレルギー疾患を処置するための非−腫瘍抗原に特異的な細胞傷害性リンパ球を生産するためのエクス−ビボプライミング |
| JP2003047482A (ja) * | 2001-05-22 | 2003-02-18 | Pfizer Prod Inc | 非アナフィラキシー誘発性ＩｇＥワクチン |
| EP1504102A2 (en) * | 2002-05-21 | 2005-02-09 | Resistentia Pharmaceuticals AB | Chimeric ige polypeptides and host cells |
| ES2316780T3 (es) * | 2002-09-05 | 2009-04-16 | Resistentia Pharmaceuticals Ab | Vacunas contra alergia. |
| US20080118524A1 (en) * | 2006-10-20 | 2008-05-22 | Stefan Persson | Anti-IgE Vaccines |
| WO2008153761A1 (en) * | 2007-05-23 | 2008-12-18 | Mastcell Pharmaceuticals, Inc. | Methods |
| WO2009142772A2 (en) | 2008-05-23 | 2009-11-26 | Mastcell Pharmaceuticals, Inc. | Methods and treatment for allergies and inflammation associated with gastrointestinal diseases |
| SG186611A1 (en) | 2008-12-09 | 2013-01-30 | Pfizer Vaccines Llc | Ige ch3 peptide vaccine |
| CA2800774A1 (en) | 2010-06-07 | 2011-12-15 | Pfizer Vaccines Llc | Ige ch3 peptide vaccine |
| US9187553B2 (en) * | 2012-01-25 | 2015-11-17 | Swey-Shen Chen | Displaying native human IgE neutralizing FcepsilonRIa-contacting IgE B-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold |
| WO2013156054A1 (en) * | 2012-04-16 | 2013-10-24 | Universität Stuttgart | The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity |
| JP5918851B2 (ja) * | 2012-06-18 | 2016-05-18 | 日本全薬工業株式会社 | ＩｇＥペプチドワクチン |
| AU2017221425A1 (en) | 2016-02-16 | 2018-08-23 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a mutant kynureninase gene |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5698201A (en) | 1973-05-07 | 1997-12-16 | The Ohio State University | Method for treatment of antigenically modified polypeptides |
| US4767842A (en) | 1973-05-07 | 1988-08-30 | The Ohio State University | Antigenic modification of polypeptides |
| US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
| US4483793A (en) | 1982-10-04 | 1984-11-20 | The Regents Of The University Of California | Dimeric oligopeptides as heptenic epitopic sites for hepatitis |
| US4703004A (en) | 1984-01-24 | 1987-10-27 | Immunex Corporation | Synthesis of protein with an identification peptide |
| US4782137A (en) | 1984-01-24 | 1988-11-01 | Immunex Corporation | Synthesis of protein with an identification peptide, and hybrid polypeptide incorporating same |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5175385A (en) | 1987-09-03 | 1992-12-29 | Ohio University/Edison Animal Biotechnolgy Center | Virus-resistant transgenic mice |
| GB8727045D0 (en) | 1987-11-19 | 1987-12-23 | Research Corp Ltd | Immunoglobulin e competitor |
| DE122006000007I1 (de) | 1987-12-31 | 2006-04-27 | Tanox Biosystems Inc | Antigene epitope, die sich ausschlisslich auf ige-tragenden B-Lymphocyten befinden. |
| US5254671A (en) * | 1990-04-27 | 1993-10-19 | Tanox Biosystems, Inc. | Extracellular segments of human e immunoglobulin anchoring peptides and antibodies specific therefor |
| JP3095168B2 (ja) | 1988-02-05 | 2000-10-03 | エル． モリソン，シェリー | ドメイン‐変性不変部を有する抗体 |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| GB8910263D0 (en) | 1989-05-04 | 1989-06-21 | Ciba Geigy Ag | Monoclonal antibodies specific for an immunoglobulin isotype |
| US5955076A (en) * | 1989-06-15 | 1999-09-21 | Peptide Therapeutics Limited | Immunoactive peptides and antibodies and their use in anti-allergy treatment |
| GB8913737D0 (en) | 1989-06-15 | 1989-08-02 | Univ Birmingham | A novel anti-allergy treatment |
| WO1991001146A1 (en) | 1989-07-14 | 1991-02-07 | Praxis Biologics, Inc. | Cytokine and hormone carriers for conjugate vaccines |
| US5733553A (en) | 1989-09-29 | 1998-03-31 | Talwar; Gursaran Prasad | Recombinant birth control vaccine |
| JP3449712B2 (ja) | 1990-01-23 | 2003-09-22 | タノックス バイオシステムズ インコーポレイテッド | ヒトε免疫グロブリン固定ペプチドの細胞外部分及びそれに特異的な抗体 |
| GB2246780B (en) * | 1990-05-25 | 1994-04-27 | Nat Res Dev | Immunodiagnostic assay for rheumatoid arthritis |
| US5196197A (en) | 1990-08-29 | 1993-03-23 | National Institute Of Immunology | Reversible fertility control for prevention of pregnancy in females |
| JPH06504438A (ja) * | 1990-12-13 | 1994-05-26 | イミュネックス・コーポレーション | 白血病抑制因子受容体 |
| SE9102808L (sv) | 1991-09-26 | 1993-03-27 | Lars T Hellman Inst F Immunolo | Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner |
| US5837686A (en) * | 1991-11-25 | 1998-11-17 | Peptide Therapeutics Limited | Peptides and antibodies for treatment of rheumatoid arthritis |
| WO1994005698A1 (en) | 1992-09-01 | 1994-03-17 | United Nations Industrial Development Organization | Peptide showing cross-reactivity with the anti-hepatitis b surface antigen antiserum |
| AU5361794A (en) | 1992-10-14 | 1994-05-09 | Board Of Trustees Of The Leland Stanford Junior University | Enhancement of b cell lymphoma tumor resistance using idiotype/cytokine conjugates |
| US5762931A (en) | 1992-12-31 | 1998-06-09 | National Institute Of Immunology | Anti-cancer utility of HCG vaccines |
| US5532142A (en) * | 1993-02-12 | 1996-07-02 | Board Of Regents, The University Of Texas System | Method of isolation and purification of fusion polypeptides |
| US5552537A (en) * | 1993-03-24 | 1996-09-03 | The Regents Of The University Of California | IgE isoforms and methods of use |
| US5501855A (en) | 1993-09-02 | 1996-03-26 | Talwar; Gursaran P. | Neem oil as a male contraceptive |
| DK96493D0 (da) | 1993-08-26 | 1993-08-26 | Mouritsen Og Elsner Aps | Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden |
| US5874085A (en) | 1993-11-10 | 1999-02-23 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Vaccine for enhanced production of IgA antibodies |
| FR2715304B1 (fr) | 1994-01-26 | 1996-04-26 | Merieux Serums Vaccins Pasteur | Vaccin anti-allergique. |
| WO1995026365A1 (en) | 1994-03-28 | 1995-10-05 | United Biomedical, Inc. | Synthetic peptide based immunogens for the treatment of allergy |
| US5651981A (en) * | 1994-03-29 | 1997-07-29 | Northwestern University | Cationic phospholipids for transfection |
| CA2203165A1 (en) | 1994-10-25 | 1996-05-02 | United Biomedical, Inc. | Synthetic ige membrane anchor peptide immunogens for the treatment of allergy |
| GB9422294D0 (en) * | 1994-11-04 | 1994-12-21 | Peptide Therapeutics Ltd | Peptides for anti-allergy treatment |
| US6949244B1 (en) | 1995-12-20 | 2005-09-27 | The Board Of Trustees Of The University Of Kentucky | Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof |
| JPH08333390A (ja) | 1995-04-07 | 1996-12-17 | Hoechst Japan Ltd | ペプチド及びそれからなる自己免疫疾患治療剤 |
| EP0839155B1 (en) * | 1995-07-17 | 2004-10-13 | Medivir UK Ltd | CYSTEINE PROTEASE INHIBITORS FOR USE IN TREATMENT OF IgE MEDIATED ALLERGIC DISEASES |
| ZA966075B (en) | 1995-07-27 | 1998-01-19 | Genentech Inc | Protein formulation. |
| US5723125A (en) * | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
| RU2193413C2 (ru) | 1996-03-01 | 2002-11-27 | Новартис Аг | Пептидные иммуногены для вакцинации и лечения аллергии |
| EP0917570A2 (en) | 1996-08-05 | 1999-05-26 | The President And Fellows Of Harvard College | Mhc binding peptide oligomers and methods of use |
| SK285639B6 (sk) | 1997-04-15 | 2007-05-03 | Pharmexa A/S | Modifikovaná ľudská TNFalfa molekula, DNA kódujúce takéto TNFalfa molekuly, spôsob výroby modifikovanej ľudskej TNFalfa molekuly, vakcíny obsahujúce modifikované TNFalfa molekuly a DNA a ich použitie |
| US6165476A (en) * | 1997-07-10 | 2000-12-26 | Beth Israel Deaconess Medical Center | Fusion proteins with an immunoglobulin hinge region linker |
| US5891432A (en) * | 1997-07-29 | 1999-04-06 | The Immune Response Corporation | Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same |
| CA2302554C (en) | 1997-09-05 | 2007-04-10 | Smithkline Beecham Biologicals S.A. | Oil in water emulsions containing saponins |
| WO1999041369A2 (en) | 1998-02-11 | 1999-08-19 | Maxygen, Inc. | Genetic vaccine vector engineering |
| US6299875B1 (en) | 1998-06-04 | 2001-10-09 | Panacea Pharmaceuticals, Llc | Methods to block IGE binding to cell surface receptors of mast cells |
| TWI227241B (en) | 1998-06-20 | 2005-02-01 | United Biomedical Inc | IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate |
| HUP0103976A3 (en) | 1998-10-05 | 2008-04-28 | Pharmexa As | Novel methods for therapeutic vaccination |
| NZ512456A (en) | 1998-11-30 | 2003-10-31 | Cytos Biotechnology Ag | Ordered molecular presentation of antigens |
| GB9908533D0 (en) | 1999-04-14 | 1999-06-09 | Novartis Ag | Organic compounds |
| CN1355846A (zh) | 1999-04-23 | 2002-06-26 | 法麦克萨有限公司 | 用于下调节白细胞介素5活性的方法 |
| AU7658101A (en) | 2000-07-28 | 2002-02-13 | Cytos Biotechnology Ag | Compositions for inducing self-specific anti-ige antibodies and uses thereof |
| US20040156838A1 (en) | 2000-09-06 | 2004-08-12 | Steen Klysner | Method for down-regulating ige |
| CN1541266A (zh) | 2001-06-15 | 2004-10-27 | 唐诚公司 | 用于治疗过敏症及哮喘病的Fcε融合蛋白 |
-
1999
- 1999-09-22 US US09/401,636 patent/US6913749B2/en not_active Expired - Fee Related
- 1999-10-21 AU AU20081/00A patent/AU771889B2/en not_active Ceased
- 1999-10-21 AT AT99963705T patent/ATE314087T1/de not_active IP Right Cessation
- 1999-10-21 IL IL14258299A patent/IL142582A0/xx not_active IP Right Cessation
- 1999-10-21 PT PT99963705T patent/PT1135158E/pt unknown
- 1999-10-21 NZ NZ511079A patent/NZ511079A/en not_active IP Right Cessation
- 1999-10-21 WO PCT/SE1999/001896 patent/WO2000025722A2/en active IP Right Grant
- 1999-10-21 DE DE69929240T patent/DE69929240T2/de not_active Expired - Lifetime
- 1999-10-21 CA CA002348756A patent/CA2348756A1/en not_active Abandoned
- 1999-10-21 JP JP2000579167A patent/JP4205861B2/ja not_active Expired - Fee Related
- 1999-10-21 ES ES99963705T patent/ES2255325T3/es not_active Expired - Lifetime
- 1999-10-21 KR KR1020017005276A patent/KR100559918B1/ko not_active IP Right Cessation
- 1999-10-21 EP EP99963705A patent/EP1135158B1/en not_active Expired - Lifetime
- 1999-10-21 PL PL99348611A patent/PL348611A1/xx not_active Application Discontinuation
- 1999-10-21 HU HU0105392A patent/HUP0105392A3/hu not_active Application Discontinuation
- 1999-10-21 DK DK99963705T patent/DK1135158T3/da active
-
2001
- 2001-04-30 NO NO20012135A patent/NO20012135L/no unknown
-
2002
- 2002-03-26 HK HK02102312A patent/HK1042844A1/xx not_active IP Right Cessation
- 2002-06-19 US US10/176,664 patent/US7459158B2/en not_active Expired - Fee Related
-
2003
- 2003-09-29 US US10/673,594 patent/US20040076625A1/en not_active Abandoned
-
2005
- 2005-09-07 JP JP2005258648A patent/JP4188353B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE69929240D1 (de) | 2006-02-02 |
| EP1135158A2 (en) | 2001-09-26 |
| ES2255325T3 (es) | 2006-06-16 |
| AU771889B2 (en) | 2004-04-08 |
| AU2008100A (en) | 2000-05-22 |
| KR100559918B1 (ko) | 2006-03-13 |
| HUP0105392A2 (hu) | 2002-04-29 |
| JP4205861B2 (ja) | 2009-01-07 |
| JP2006068015A (ja) | 2006-03-16 |
| WO2000025722A2 (en) | 2000-05-11 |
| US20010038843A1 (en) | 2001-11-08 |
| US7459158B2 (en) | 2008-12-02 |
| JP4188353B2 (ja) | 2008-11-26 |
| NZ511079A (en) | 2003-08-29 |
| JP2002531064A (ja) | 2002-09-24 |
| US6913749B2 (en) | 2005-07-05 |
| PL348611A1 (en) | 2002-06-03 |
| HK1042844A1 (en) | 2002-08-30 |
| DK1135158T3 (da) | 2006-05-15 |
| EP1135158B1 (en) | 2005-12-28 |
| KR20010089364A (ko) | 2001-10-06 |
| CA2348756A1 (en) | 2000-05-11 |
| US20030031663A1 (en) | 2003-02-13 |
| ATE314087T1 (de) | 2006-01-15 |
| NO20012135L (no) | 2001-06-25 |
| PT1135158E (pt) | 2006-05-31 |
| HUP0105392A3 (en) | 2008-04-28 |
| NO20012135D0 (no) | 2001-04-30 |
| WO2000025722A3 (en) | 2000-10-12 |
| DE69929240T2 (de) | 2006-08-31 |
| US20040076625A1 (en) | 2004-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL142582A0 (en) | Enhanced vaccines | |
| NO20210499A1 (no) | Humanisert, glykoomkonstruert Type II anti-CD20 antistoff og anvendelse derav, samt vertscelle og farmasøytisk sammensetning | |
| CY1122505T1 (el) | Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn | |
| CY1121353T1 (el) | Anti-tnf αντισωματα, συνθεσεις, μεθοδοi και χρησεις | |
| DE602004031017D1 (de) | Zusammensetzung verpackte virusartige teilchen umfassend zur verstärkung einer immunantwort | |
| YU9403A (sh) | Anti-dualna antitela integrina, kompozicije, postupci i primene | |
| HK1086750A1 (en) | Pharmaceutical composition for inducing an immune response in a human or animal | |
| BR0207283A (pt) | Anticorpos anti-egfr modificados com imunogenicidade reduzida | |
| WO2005000246A3 (en) | Methods and compositions for treating rheumatoid arthritis | |
| HK1039749B (zh) | Ctl表位和t輔助淋巴細胞表位在免疫接種中的應用 | |
| HK1026911A1 (en) | Novel method for the production of antihuman antigen receptors and uses thereof | |
| CO5070644A1 (es) | Vacunas que comprenden proteinas e6 de hpv y/o e7 de hpv junto con un oligonucleotido cpg como adyudante | |
| HUP9702359A2 (hu) | Monoklonális antitest, eljárás monoklonális antitest előállítására, valamint a monoklonális antitestet tartalmazó gyógyászati készítmény és diagnosztikai reagens | |
| TR200102034T2 (tr) | Anti kanser aşılaması için antikorların kullanılması | |
| NO20052714D0 (no) | Fremgangsmater og materialer for behandling av inflammatoriske tilstander | |
| BR0009781A (pt) | Anticorpos antiidiotìpicos contra anticorpos que inibem a ligação de imunoglobulina e ao seu receptor de alta afinidade | |
| BR0207528A (pt) | Anticorpo, composição farmacêutica, e, usos de uma quantidade efetiva de um agente, de uma quantidade terapeuticamente efetiva de um anticorpo para il-22, de uma quantidade imunogênica do antìgeno e uma quantidade aumentadora de imunogenicidade de il-22 em combinação, de uma quantidade efetiva do anticorpo ou fragmento do mesmo e de uma quantidade suficiente de anticorpo ou fragmento ligado a antìgeno do mesmo | |
| WO2001009298A3 (en) | Strategy for carbohydrate-based cancer vaccines | |
| Hyslop et al. | The influence of aluminium hydroxide content, dose volume and the inclusion of saponin on the efficacy of inactivated foot-and-mouth disease vaccines | |
| SE9903534L (sv) | Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning | |
| EP1621209A3 (en) | Vaccines based on domains of chimeric immunoglobulin E peptides | |
| Skea et al. | Adhesion-mediated enhancement of the adjuvant activity of alum | |
| WO2002038611A3 (en) | Method of producing antibodies by immunization with conjugates of molecules coupled to charge-modified proteins | |
| Lou et al. | Destruction of zona pellucida of ovulated oocytes by anti-ZP3 antibodies: a potential mechanism of ZP-based contraceptive vaccine | |
| TH44467A (th) | วัคซีนแคมไพโลแบคเตอร์ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |